REFRACTORY AL AMYLOIDOSIS
Clinical trials for REFRACTORY AL AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY AL AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for REFRACTORY AL AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat amyloidosis patients with prior drug exposure
Disease control OngoingThis study tests whether adding daratumumab to pomalidomide and dexamethasone can improve complete remission rates in people with light chain amyloidosis whose disease has returned or not responded after prior daratumumab treatment. About 15 adults with measurable disease who hav…
Matched conditions: REFRACTORY AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 26, 2026 10:14 UTC
-
New drug cocktail targets Hard-to-Treat amyloidosis in early trial
Disease control OngoingThis early-stage trial is testing a combination of three drugs (venetoclax, ixazomib, and dexamethasone) in 24 people with a rare blood disease called light chain amyloidosis that has returned or not responded to prior treatments. The study only includes patients with a specific …
Matched conditions: REFRACTORY AL AMYLOIDOSIS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC